Patents by Inventor Logan E. Vine

Logan E. Vine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS FOR FGFR INHIBITION
    Publication number: 20250270211
    Abstract: A compound having the following structure of Formula (IV): or a stereoisomer, salt, or tautomer thereof, wherein R1, R2, R3, A, B, X, and Y are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.
    Type: Application
    Filed: May 13, 2025
    Publication date: August 28, 2025
    Inventors: Jay Bradford Fell, John E. Robinson, John P. Fischer, Logan E. Vine, Martha E. Rodriguez, Jennifer Fulton, Tanna Bettendorf, Bradley J. Newhouse, Robert A. Rieger, Cori A. Malinky, Aaron Christopher Smith, Ravi Kumar Jalluri, Mark Joseph Chicarelli, Leah J. Salituro, Macedonio J. Mejia
  • Compounds for FGFR inhibition
    Patent number: 12351581
    Abstract: A compound having the following structure of Formula (IV): or a stereoisomer, salt, or tautomer thereof, wherein R1, R2, R3, A, B, X, and Y are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.
    Type: Grant
    Filed: August 19, 2024
    Date of Patent: July 8, 2025
    Assignee: Cogent Biosciences, Inc.
    Inventors: Jay Bradford Fell, John E. Robinson, John P. Fischer, Logan E. Vine, Martha E. Rodriguez, Jennifer Fulton, Tanna Bettendorf, Bradley J. Newhouse, Robert A. Rieger, Cori A. Malinky, Aaron Christopher Smith, Ravi Kumar Jalluri, Mark Joseph Chicarelli, Leah J. Salituro, Macedonio J. Mejia
  • PI3K INHIBITORS
    Publication number: 20250206752
    Abstract: A compound having the following structure of Formula (I): or a stereoisomer of the compound, tautomer of the compound, pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R8, A, X, Z, and Y are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.
    Type: Application
    Filed: February 7, 2025
    Publication date: June 26, 2025
    Inventors: Payal Chatterjee, Mark J. Chicarelli, Michael L. Conner, John Fischer, Jennifer Fulton, Ravi Kumar Jalluri, Hailey J. Knox, Vijay Kumar, Bradley J. Newhouse, Martha E. Rodriguez, Leah J. Salituro, Aaron C. Smith, Lee M. Stunkard, Yeyun Zhou, Paul R. Carlson, Scott W. Niman, Patrick J. Sutter, John I. Trujillo, Logan E. Vine, Brooklynn Venteicher
  • ERBB2 INHIBITORS
    Publication number: 20250129078
    Abstract: A compound having the following structure of Formula (I): or a stereoisomer of the compound, pharmaceutically acceptable salt, or tautomer thereof, wherein E, L, R3a, R3b, R3c, R3d, R5b, R8, Y1, Y2, Y3, Y4, Y5, Y6, X1, X2, Z1, and Z2 are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.
    Type: Application
    Filed: April 10, 2024
    Publication date: April 24, 2025
    Inventors: Leah J. Salituro, Jennifer Fulton, Ravi Kumar Jalluri, Logan E. Vine, Tanna Bettendorf, John Fischer, Jay B. Fell, Mark J. Chicarelli, Payal Chatterjee, Cori A. Malinky
  • PI3K inhibitors
    Patent number: 12281122
    Abstract: A compound having the following structure of Formula (I): or a stereoisomer of the compound, tautomer of the compound, pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R8, A, X, Z, and Y are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.
    Type: Grant
    Filed: August 5, 2024
    Date of Patent: April 22, 2025
    Assignee: COGENT BIOSCIENCES, INC.
    Inventors: Payal Chatterjee, Mark J. Chicarelli, Michael L. Conner, John Fischer, Jennifer Fulton, Ravi Kumar Jalluri, Hailey J. Knox, Vijay Kumar, Bradley J. Newhouse, Martha E. Rodriguez, Leah J. Salituro, Aaron C. Smith, Lee M. Stunkard, Yeyun Zhou, Paul R. Carlson, Scott W. Niman, Patrick J. Sutter, John I. Trujillo, Logan E. Vine, Brooklynn Venteicher
  • COMPOUNDS FOR FGFR INHIBITION
    Publication number: 20250066352
    Abstract: A compound having the following structure of Formula (IV): or a stereoisomer, salt, or tautomer thereof, wherein R1, R2, R3, A, B, X, and Y are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.
    Type: Application
    Filed: August 19, 2024
    Publication date: February 27, 2025
    Inventors: Jay Bradford Fell, John E. Robinson, John P. Fischer, Logan E. Vine, Martha E. Rodriguez, Jennifer Fulton, Tanna Bettendorf, Bradley J. Newhouse, Robert A. Rieger, Cori A. Malinky, Aaron Christopher Smith, Ravi Kumar Jalluri, Mark Joseph Chicarelli, Leah J. Salituro, Macedonio J. Mejia
  • COMPOUNDS FOR FGFRS INHIBITORS
    Publication number: 20240270741
    Abstract: A compound having the following structure of Formula (I): or a stereoisomer, salt, or tautomer thereof, wherein R1, R2, R5, A, B, X, and Y are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.
    Type: Application
    Filed: January 9, 2024
    Publication date: August 15, 2024
    Inventors: Jay Bradford Fell, John E. Robinson, John P. Fischer, Logan E. Vine, Martha E. Rodriguez, Jennifer Fulton, Tanna Bettendorf, Bradley J. Newhouse, Robert A. Rieger, Cori A. Malinky, Aaron Christopher Smith, Toya D. Scaggs, Joshua Dahlke, Ravi Kumar Jalluri, Mark Joseph Chicarelli, Leah J. Salituro, Macedonio J. Mejia, Payal Chatterjee